TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive In Brief: FDA Stops Imports Of Counterfeit Adriamychin; Rosenburg: NIH Pay 25-33% That Of Academia April 22, 1988
TCL Archive FDA Caps Advisors’ Holdings To $50,000 In Firms Affected By Committee Meetings. August 8, 2008
TCL Archive Study Attributes Drop In Breast Cancer Incidence To Decline In Hormone Replacement. December 15, 2006
